Home Semiconductor & Electronics Electronic Components Dopamine Agonists Market

Dopamine Agonists Market Size, Share & Trends Analysis Report By Indication (Parkinson's disease, Restless legs syndrome, Hyperprolactinemia, Others), By Drug Type (Ergot Alkaloids, Non-Ergot Dopamine Agonists), By Route of Administration (Oral, Injectable, Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Other Pharmacies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: July 24, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Table Of Content

  1. Executive Summary
  2. Research Scope & Segmentation
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
  3. Market Opportunity Assessment
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
  4. Market Trends
    1. Drivers
    2. Market Warning Factors
    3. Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
  5. Market Assessment
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
  6. Dopamine Agonists Market Size Analysis
    1. Introduction
    2. Dopamine Agonists Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Parkinson's disease
      2. Restless legs syndrome
      3. Hyperprolactinemia
      4. Others
    3. Dopamine Agonists Market Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
      1. Ergot Alkaloids
      2. Non-Ergot Dopamine Agonists
    4. Dopamine Agonists Market Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
      1. Oral
      2. Injectable
      3. Others
    5. Dopamine Agonists Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Other Pharmacies
  7. North America Dopamine Agonists Market Size Analysis
    1. Introduction
    2. Dopamine Agonists Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Parkinson's disease
      2. Restless legs syndrome
      3. Hyperprolactinemia
      4. Others
    3. Dopamine Agonists Market Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
      1. Ergot Alkaloids
      2. Non-Ergot Dopamine Agonists
    4. Dopamine Agonists Market Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
      1. Oral
      2. Injectable
      3. Others
    5. Dopamine Agonists Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Other Pharmacies
    6. U.S.
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
    7. Canada
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
  8. Europe Dopamine Agonists Market Size Analysis
    1. Introduction
    2. Dopamine Agonists Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Parkinson's disease
      2. Restless legs syndrome
      3. Hyperprolactinemia
      4. Others
    3. Dopamine Agonists Market Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
      1. Ergot Alkaloids
      2. Non-Ergot Dopamine Agonists
    4. Dopamine Agonists Market Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
      1. Oral
      2. Injectable
      3. Others
    5. Dopamine Agonists Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Other Pharmacies
    6. U.K.
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
    7. Germany
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
    8. France
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
    9. Spain
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
    10. Italy
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
    11. Russia
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
    12. Nordic
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
    13. Benelux
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
    14. Rest of Europe
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
  9. APAC Dopamine Agonists Market Size Analysis
    1. Introduction
    2. Dopamine Agonists Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Parkinson's disease
      2. Restless legs syndrome
      3. Hyperprolactinemia
      4. Others
    3. Dopamine Agonists Market Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
      1. Ergot Alkaloids
      2. Non-Ergot Dopamine Agonists
    4. Dopamine Agonists Market Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
      1. Oral
      2. Injectable
      3. Others
    5. Dopamine Agonists Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Other Pharmacies
    6. China
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
    7. Korea
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
    8. Japan
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
    9. India
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
    10. Australia
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
    11. Taiwan
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
    12. South East Asia
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
    13. Rest of Asia-Pacific
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
  10. Middle East and Africa Dopamine Agonists Market Size Analysis
    1. Introduction
    2. Dopamine Agonists Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Parkinson's disease
      2. Restless legs syndrome
      3. Hyperprolactinemia
      4. Others
    3. Dopamine Agonists Market Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
      1. Ergot Alkaloids
      2. Non-Ergot Dopamine Agonists
    4. Dopamine Agonists Market Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
      1. Oral
      2. Injectable
      3. Others
    5. Dopamine Agonists Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Other Pharmacies
    6. UAE
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
    7. Turkey
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
    8. Saudi Arabia
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
    9. South Africa
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
    10. Egypt
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
    11. Nigeria
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
    12. Rest of MEA
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
  11. LATAM Dopamine Agonists Market Size Analysis
    1. Introduction
    2. Dopamine Agonists Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Parkinson's disease
      2. Restless legs syndrome
      3. Hyperprolactinemia
      4. Others
    3. Dopamine Agonists Market Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
      1. Ergot Alkaloids
      2. Non-Ergot Dopamine Agonists
    4. Dopamine Agonists Market Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
      1. Oral
      2. Injectable
      3. Others
    5. Dopamine Agonists Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Other Pharmacies
    6. Brazil
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
    7. Mexico
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
    8. Argentina
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
    9. Chile
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
    10. Colombia
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
    11. Rest of LATAM
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      4. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
  12. Competitive Landscape
    1. Dopamine Agonists Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    3. Tier Structure Analysis
    4. Recent Developments
  13. Market Players Assessment
    1. Teva Pharmaceutical Industries Ltd
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Supernus Pharmaceuticals
    3. Lundbeck A/S
    4. AbbVie Inc.
    5. Novartis AG
    6. Amneal Pharmaceuticals LLC
    7. Reddy’s Laboratories Ltd
    8. Intas Pharmaceuticals Ltd.
    9. GLENMARK PHARMACEUTICALS LTD.
    10. Zydus Group
    11. Hikma Pharmaceuticals PLC
    12. TORRENT PHARMACEUTICALS LTD.
    13. Apotex Inc.
    14. Alto Neuroscience, Inc.
    15. Mylan N.V.
    16. Kyowa Kirin Co., Ltd.
    17. Neurocrine Biosciences, Inc.,
    18. Acorda Therapeutics, Inc.
    19. Acadia Pharmaceuticals Inc.
    20. Hoffmann-La Roche Ltd 
    21. Others
  14. Research Methodology
    1. Research Data
      1. Secondary Data
        1. Major Secondary Sources
        2. Key Data from Secondary Sources
      2. Primary Data
        1. Key Data from Primary Sources
        2. Breakdown of Primaries
      3. Secondary And Primary Research
        1. Key Industry Insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
  15. Appendix
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  16. Disclaimer
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.